3D Cell Culture Global Market - Forecast to 2024

Publishing Date : February, 2018
Report Code : HCBT0106
Price:
Single license $4,950
Site license $6,750
Global license $9,000


3D cell culture is the method of creating an artificial environment that allows the cells to grow and interact within 3D structures. According to IQ4I analysis, the 3D cell culture global market is expected to grow at double digit CAGR to reach $1,485.1 million by 2024. Substantial R&D investments, use of 3D cell culture models in drug discovery and research as alternative to animal testing, emergence of microfluidic technology and bioprinting and increasing focus on regenerative medicine are some of the driving factors for this industry. However, lack of experienced and skilled professionals, budget restrictions for small and medium sized laboratories, lack of consistency in 3D cell culture products, stringent process controls for handling capabilities and ethical concerns over the use of animal sources are hindering the market to grow.


3D cell culture global market is classified based on technology, products, application, end-users, and geography. Based on technology the 3D cell culture market can be divided into two segments i.e., Scaffold based approaches and Scaffold free approaches. The scaffold based approaches are further classified into scaffolds, hydrogels and others. The scaffold free approaches are classified as the hang drop method, forced floating, agitation based methods, and microfludics. Based on products the segment is further classified as cells and tissues, media, sera and reagents, microplates and others, assay kits, scaffolds, and others (bioreactors and incubators). The application segment can be classified as basic research, toxicity and drug screening, tissue engineering, stem cell research, drug discovery, gene therapy and cancer research. The end-users segment can be classified as academic institutes, biotechnology and pharmaceutical industries and others.

Based on geography 3D cell culture global market is classified as North America, Europe, APAC and Rest of the world. North America accounts for the highest market share of 46.2% followed by Europe. However, Asian countries especially China and Japan are the fastest growing regions with its growing demand for 3D cell culture products.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Others

• Europe
o Germany
o U.K.
o France
o Others

• Asia-Pacific
o China
o Japan
o Korea
o Others


• Rest of the World (RoW)
o Brazil
o Rest of Latin America
o Middle-East and Others

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     SUBSTANTIAL R&D INVESTMENTS FOR 3D CELL CULTURE
        • 3.3.1.2     USE OF 3D CELL CULTURE MODELS IN DRUG DISCOVERY AND RESEARCH AS AN ALTERNATIVE TO ANIMAL TESTING
        • 3.3.1.3     EMERGENCE OF MICROFLUIDIC TECHNOLOGY AND BIOPRINTING
        • 3.3.1.4     INCREASING FOCUS ON REGENERATIVE MEDICINE
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     LACK OF EXPERIENCED AND SKILLED PROFESSIONALS
        • 3.3.2.2     BUDGET RESTRICTION FOR SMALL AND MEDIUM SIZED LABORATORIES AND LACK OF CONSISTENCY IN 3D CELL CULTURE PRODUCTS
        • 3.3.2.3     STRINGENT PROCESS CONTROLS FOR ADVANCED HANDLING CAPABILITIES
        • 3.3.2.4     ETHICAL CONCERN OVER USE OF ANIMAL SOURCES
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     UNITED STATES
      • 3.4.2     EUROPE
      • 3.4.3     INDIA
      • 3.4.4     JAPAN
    • 3.5     TECHNOLOGICAL ADVANCEMENTS
      • 3.5.1     INTRODUCTION
      • 3.5.2     ORGAN-ON-CHIP
      • 3.5.3     3D BIOPRINTING
      • 3.5.4     SINGLE USE REACTORS
    • 3.6     PORTER’S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     BARGAINING POWER OF SUPPLIERS
      • 3.6.4     BARGAINING POWER OF BUYERS
      • 3.6.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.7     SUPPLY CHAIN ANALYSIS
      • 3.7.1     RAW MATERIAL SUPPLIER:
      • 3.7.2     PRODUCT MANUFACTURERS:-
      • 3.7.3     3D CELL CULTURE PRODUCTS DISTRIBUTORS
      • 3.7.4     END-USERS
    • 3.8     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
  • 4     3D CELL CULTURE GLOBAL MARKET, BY TECHNOLOGY
    • 4.1     INTRODUCTION
    • 4.2     SCAFFOLD BASED PLATFORMS
      • 4.2.1     SCAFFOLDS
      • 4.2.2     HYDROGELS
      • 4.2.3     OTHERS
    • 4.3     SCAFFOLD FREE PLATFORMS
      • 4.3.1     HANG DROP METHOD
      • 4.3.2     FORCED FLOATING
      • 4.3.3     AGITATION BASED METHODS
      • 4.3.4     MICROFLUIDICS
  • 5     3D CELL CULTURE GLOBAL MARKET, BY PRODUCTS
    • 5.1     INTRODUCTION
    • 5.2     CELLS AND TISSUES
    • 5.3     MEDIA, SERA AND REAGENTS
    • 5.4     MICROPLATES AND OTHERS
    • 5.5     ASSAY KITS
    • 5.6     SCAFFOLDS
      • 5.6.1     NATURAL SCAFFOLDS
      • 5.6.2     SYNTHETIC SCAFFOLDS
      • 5.6.3     HYBRID COMPOSITE
      • 5.6.4     HYDROGELS
    • 5.7     OTHERS
  • 6     3D CELL CULTURE GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     BASIC RESEARCH
    • 6.3     TOXICITY AND DRUG SAFETY SCREENING
    • 6.4     TISSUE ENGINEERING
    • 6.5     STEM CELL RESEARCH
    • 6.6     DRUG DISCOVERY
    • 6.7     CANCER RESEARCH
    • 6.8     GENE THERAPY
  • 7     3D CELL CULTURE GLOBAL MARKET, BY END-USERS
    • 7.1     INTRODUCTION
    • 7.2     ACADEMIC INSTITUTES
    • 7.3     BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES
    • 7.4     OTHERS
  • 8     REGIONAL ANALYSIS
    • 8.1     INTRODUCTION
    • 8.2     NORTH AMERICA
      • 8.2.1     U.S.
      • 8.2.2     OTHERS
    • 8.3     EUROPE
      • 8.3.1     GERMANY
      • 8.3.2     U.K.
      • 8.3.3     FRANCE
      • 8.3.4     OTHERS
    • 8.4     ASIA-PACIFIC
      • 8.4.1     CHINA
      • 8.4.2     JAPAN
      • 8.4.3     KOREA
      • 8.4.4     OTHERS
    • 8.5     REST OF THE WORLD
      • 8.5.1     BRAZIL
      • 8.5.2     REST OF LATIN AMERICA
      • 8.5.3     MIDDLE EAST AND OTHERS
  • 9     COMPETITIVE LANDSCAPE
    • 9.1     INTRODUCTION
    • 9.2     COLLABORATIONS & PARTNERSHIPS
    • 9.3     NEW PRODUCT LAUNCHES
    • 9.4     AGREEMENTS, EXPANTIONS & MERGERS
    • 9.5     COMPANY MATRIX
  • 10     MAJOR COMPANIES
    • 10.1     BECTON DICKINSON AND COMPANY
      • 10.1.1     OVERVIEW
      • 10.1.2     FINANCIALS
      • 10.1.3     PRODUCT PORTFOLIO
      • 10.1.4     KEY DEVELOPMENTS
      • 10.1.5     BUSINESS STRATEGY
      • 10.1.6     SWOT ANALYSIS
    • 10.2     CORNING INCORPORATED
      • 10.2.1     OVERVIEW
      • 10.2.2     FINANCIALS
      • 10.2.3     PRODUCT PORTFOLIO
      • 10.2.4     KEY DEVELOPMENTS
      • 10.2.5     BUSINESS STRATEGY
      • 10.2.6     SWOT ANALYSIS
    • 10.3     INSPHERO AG
      • 10.3.1     OVERVIEW
      • 10.3.2     FINANCIALS
      • 10.3.3     PRODUCT PORTFOLIO
      • 10.3.4     KEY DEVELOPMENTS
      • 10.3.5     BUSINESS STRATEGY
      • 10.3.6     SWOT ANALYSIS
    • 10.4     JSR CORPORATION (ORGANOGENIX INC.)
      • 10.4.1     OVERVIEW
      • 10.4.2     FINANCIALS
      • 10.4.3     PRODUCT PORTFOLIO
      • 10.4.4     KEY DEVELOPMENTS
      • 10.4.5     BUSINESS STRATEGY
      • 10.4.6     SWOT ANALYSIS
    • 10.5     KURARAY CO. LTD
      • 10.5.1     OVERVIEW
      • 10.5.2     FINANCIALS
      • 10.5.3     PRODUCT PORTFOLIO
      • 10.5.4     KEY DEVELOPMENTS
      • 10.5.5     BUSINESS STRATEGY
      • 10.5.6     SWOT ANALYSIS
    • 10.6     LONZA GROUP
      • 10.6.1     OVERVIEW
      • 10.6.2     FINANCIALS
      • 10.6.3     SERVICE PORTFOLIO
      • 10.6.4     KEY DEVELOPMENTS
      • 10.6.5     BUSINESS STRATEGY
      • 10.6.6     SWOT ANALYSIS
    • 10.7     MERCK KGAA
      • 10.7.1     OVERVIEW
      • 10.7.2     FINANCIALS
      • 10.7.3     PRODUCT PORTFOLIO
      • 10.7.4     KEY DEVELOPMENTS
      • 10.7.5     BUSINESS STRATEGY
      • 10.7.6     SWOT ANALYSIS
    • 10.8     NANO 3D BIOSCIENCES, INC
      • 10.8.1     OVERVIEW
      • 10.8.2     FINANCIALS
      • 10.8.3     PRODUCT PORTFOLIO
      • 10.8.4     KEY DEVELOPMENTS
      • 10.8.5     BUSINESS STRATEGY
      • 10.8.6     SWOT ANALYSIS
    • 10.9     ORGANOVO HOLDINGS INC.
      • 10.9.1     OVERVIEW
      • 10.9.2     FINANCIALS
      • 10.9.3     PRODUCT PORTFOLIO
      • 10.9.4     KEY DEVELOPMENTS
      • 10.9.5     BUSINESS STRATEGY
      • 10.9.6     SWOT ANALYSIS
    • 10.10     THERMO FISHER SCIENTIFIC, INC
      • 10.10.1     OVERVIEW
      • 10.10.2     FINANCIALS
      • 10.10.3     PRODUCT PORTFOLIO
      • 10.10.4     KEY DEVELOPMENTS
      • 10.10.5     BUSINESS STRATEGY
      • 10.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     3D CELL CULTURE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 2     3D CELL CULTURE GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2016-2024) ($MN)
      • TABLE 3     SCAFFOLD BASED PLATFORMS GLOBAL MARKET REVENUE, BY TYPE, (2016-2024) ($MN)
      • TABLE 4     SCAFFOLD BASED PLATFORMS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 5     SCAFFOLDS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 6     HYDROGELS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 7     OTHERS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 8     SCAFFOLD FREE PLATFORMS GLOBAL MARKET REVENUE, BY TYPE, (2016-2024) ($MN)
      • TABLE 9     SCAFFOLD FREE PLATFORMS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 10     HANGDROP METHOD MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 11     FORCED FLOATING MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 12     AGITATION BASED METHODS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 13     MICROFLUIDICS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 14     3D CELL CULTURE GLOBAL MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
      • TABLE 15     CELLS & TISSUES MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 16     MEDIA, SERA & REAGENTS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 17     MICROPLATES & OTHERS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 18     ASSAY KITS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 19     SCAFFOLDS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 20     SCAFFOLDS GLOBAL MARKET REVENUE, BY TYPE, (2016-2024) ($MN)
      • TABLE 21     NATURAL SCAFFOLDS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 22     SYNTHETIC SCAFFOLDS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 23     HYBRID COMPOSITE MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 24     HYDROGELS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 25     OTHERS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 26     3D CELL CULTURE GLOBAL MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 27     BASIC REASEARCH MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 28     TOXICITY AND DRUG SAFETY SCREENING MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 29     TISSUE ENGINEERING MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 30     STEM CELL RESEARCH MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 31     DRUG DISCOVERY MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 32     CANCER RESEARCH MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 33     GENE THERAPY MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 34     3D CELL CULTURE GLOBAL MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 35     ACADEMIC INSTITUTES MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 36     BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 37     OTHERS MARKET REVENUE, BY REGIONS, (2016-2024) ($MN)
      • TABLE 38     3D CELL CULTURE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 39     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY (2016-2024) ($MN)
      • TABLE 40     NORTH AMERICA SCAFFOLD BASED PLATFORMS MARKET REVENUE, BY TYPE (2016-2024) ($MN)
      • TABLE 41     NORTH AMERICA SCAFFOLD FREE PLATFORMS MARKET REVENUE, BY TYPE (2016-2024) ($MN)
      • TABLE 42     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
      • TABLE 43     NORTH AMERICA SCAFFOLDS MARKET REVENUE, BY TYPE, (2016-2024) ($MN)
      • TABLE 44     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 45     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 46     EUROPE 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY (2016-2024) ($MN)
      • TABLE 47     EUROPE SCAFFOLD BASED PLATFORMS MARKET REVENUE, BY TYPE (2016-2024) ($MN)
      • TABLE 48     EUROPE SCAFFOLD FREE PLATFORMS MARKET REVENUE, BY TYPE (2016-2024) ($MN)
      • TABLE 49     EUROPE 3D CELL CULTURE MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
      • TABLE 50     EUROPE SCAFFOLDS MARKET REVENUE, BY TYPE, (2016-2024) ($MN)
      • TABLE 51     EUROPE 3D CELL CULTURE MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 52     EUROPE 3D CELL CULTURE MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 53     APAC 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY (2016-2024) ($MN)
      • TABLE 54     APAC SCAFFOLD BASED PLATFORMS MARKET REVENUE, BY TYPE (2016-2024) ($MN)
      • TABLE 55     APAC SCAFFOLD FREE PLATFORMS MARKET REVENUE, BY TYPE (2016-2024) ($MN)
      • TABLE 56     APAC 3D CELL CULTURE MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
      • TABLE 57     APAC SCAFFOLDS MARKET REVENUE, BY TYPE, (2016-2024) ($MN)
      • TABLE 58     APAC 3D CELL CULTURE MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 59     APAC 3D CELL CULTURE MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 60     ROW 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY (2016-2024) ($MN)
      • TABLE 61     ROW SCAFFOLD BASED PLATFORMS MARKET REVENUE, BY TYPE (2016-2024) ($MN)
      • TABLE 62     ROW SCAFFOLD FREE PLATFORMS MARKET REVENUE, BY TYPE (2016-2024) ($MN)
      • TABLE 63     ROW 3D CELL CULTURE MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
      • TABLE 64     ROW SCAFFOLDS MARKET REVENUE, BY TYPE, (2016-2024) ($MN)
      • TABLE 65     ROW 3D CELL CULTURE MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 66     ROW 3D CELL CULTURE MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 67     COLLABORATIONS & PARTNERSHIPS (JAN 2016 – JAN 2018)
      • TABLE 68     NEW PRODUCT LAUNCH(JAN 2016 – JAN 2018)
      • TABLE 69     AGREEMENTS, EXPANTIONS & MERGERS (JAN 2016 – JAN 2018)
      • TABLE 70     COMPANY MATRIX: COMPANY V/S PRODUCT OFFERING
      • TABLE 71     BECTON DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 72     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 73     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 74     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 75     CORNING INCORPORATED: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 76     CORNING INCORPORATED: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
      • TABLE 77     CORNING INCORPORATED: TOTAL REVENUE, BY GEOGRAPHY (2012-2014) ($MN)
      • TABLE 78     KURARAY CO. LTD: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 79     KURARAY CO. LTD. : TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
      • TABLE 80     KURARAY CO. LTD: TOTAL REVENUE, BY GEOGRAPHY (2012-2014) ($MN)
      • TABLE 81     LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 82     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
      • TABLE 83     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 84     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 85     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 86     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 87     ORGANOVO HOLDINGS INC.: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 88     THERMO FISHER SCIENTIFIC, INC: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 89     THERMO FISHER SCIENTIFIC, INC : TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
      • TABLE 90     THERMO FISHER SCIENTIFIC, INC: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)

      LIST OF FIGURES

      • FIGURE 1     GLOBAL 3D CELL CULTURE MARKET SHARE AND REVENUE, BY REGION, (2016-2024) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: 3D CELL CULTURE GLOBAL MARKET
      • FIGURE 3     3D CELL CULTURE GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     3D CELL CULTURE GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     3D CELL CULTURE: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     3D CELL CULTURE GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 8     3D CELL CULTURE MARKET: PORTER’S ANALYSIS
      • FIGURE 9     3D CELL CULTURE GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     3D CELL CULTURE GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2017
      • FIGURE 11     3D CELL CULTURE GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2017-2024) ($MN)
      • FIGURE 12     3D CELL CULTURE SCAFFOLD BASED PLATFORMS GLOBAL MARKET REVENUE, BY TYPE, (2017) ($MN)
      • FIGURE 13     3D CELL CULTURE SCAFFOLD FREE PLATFORMS GLOBAL MARKET REVENUE, BY TYPE, (2017) ($MN)
      • FIGURE 14     SCAFFOLD BASED PLATFORMS GLOBAL MARKET REVENUE, BY TYPE, (2016-2024) ($MN)
      • FIGURE 15     SCAFFOLD FREE PLATFORMS GLOBAL MARKET REVENUE, BY TYPE, (2016-2024) ($MN)
      • FIGURE 16     3D CELL CULTURE GLOBAL MARKET REVENUE, BY PRODUCT, (2017 V/S 2024) ($MN)
      • FIGURE 17     SCAFFOLDS GLOBAL MARKET REVENUE, BY TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 18     3D CELL CULTURE GLOBAL MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 19     3D CELL CULTURE GLOBAL MARKET SHARE, BY APPLICATION, (2017) (%) CAGR (%)
      • FIGURE 20     3D CELL CULTURE GLOBAL MARKET REVENUE, BY END-USERS, (2017 V/S 2024) ($MN)
      • FIGURE 21     3D CELL CULTURE GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • FIGURE 22     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY (2017 VS 2024) ($MN)
      • FIGURE 23     NORTH AMERICA SCAFFOLD BASED PLATFORMS & SCAFFOLD FREE PLATFORM MARKET, BY TYPE (2017 VS 2024) ($MN)
      • FIGURE 24     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 25     NORTH AMERICA SCAFFOLDS MARKET REVENUE, BY TYPE (2017 VS 2024) ($MN)
      • FIGURE 26     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BY APPLICATION (2017 VS 2024) ($MN)
      • FIGURE 27     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 28     U.S. 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 29     U.S. 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 30     OTHER NORTH AMERICAN COUNTRIES 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 31     OTHER NORTH AMERICAN COUNTRIES 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 32     EUROPE 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY (2017 VS 2024) ($MN)
      • FIGURE 33     EUROPE SCAFFOLD BASED PLATFORMS & SCAFFOLD FREE PLATFORM MARKET, BY TYPE (2017 VS 2024) ($MN)
      • FIGURE 34     EUROPE 3D CELL CULTURE MARKET REVENUE, BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 35     EUROPE SCAFFOLDS MARKET REVENUE, BY TYPE (2017 VS 2024) ($MN)
      • FIGURE 36     EUROPE 3D CELL CULTURE MARKET REVENUE, BY APPLICATION (2017 VS 2024) ($MN)
      • FIGURE 37     EUROPE 3D CELL CULTURE MARKET REVENUE, BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 38     GERMANY 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 39     GERMANY 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 40     U.K. 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 41     U.K. 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 42     FRANCE 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 43     FRANCE 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 44     OTHER EUROPEAN COUNTRIES 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 45     OTHER EUROPEAN COUNTRIES 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 46     APAC 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY (2017 VS 2024) ($MN)
      • FIGURE 47     APAC SCAFFOLD BASED PLATFORMS & SCAFFOLD FREE PLATFORM MARKET, BY TYPE (2017 VS 2024) ($MN)
      • FIGURE 48     APAC 3D CELL CULTURE MARKET REVENUE, BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 49     APAC SCAFFOLDS MARKET REVENUE, BY TYPE (2017 VS 2024) ($MN)
      • FIGURE 50     APAC 3D CELL CULTURE MARKET REVENUE, BY APPLICATION (2017 VS 2024) ($MN)
      • FIGURE 51     APAC 3D CELL CULTURE MARKET REVENUE, BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 52     CHINA 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 53     CHINA 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 54     JAPAN 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 55     JAPAN 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 56     KOREA 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 57     KOREA 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 58     OTHER APAC COUNTRIES 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 59     OTHER APAC COUNTRIES 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 60     ROW 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY (2017 VS 2024) ($MN)
      • FIGURE 61     ROW SCAFFOLD BASED PLATFORMS & SCAFFOLD FREE PLATFORM MARKET, BY TYPE (2017 VS 2024) ($MN)
      • FIGURE 62     ROW 3D CELL CULTURE MARKET REVENUE, BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 63     ROW SCAFFOLDS MARKET REVENUE, BY TYPE (2017 VS 2024) ($MN)
      • FIGURE 64     ROW 3D CELL CULTURE MARKET REVENUE, BY APPLICATION (2017 VS 2024) ($MN)
      • FIGURE 65     ROW 3D CELL CULTURE MARKET REVENUE, BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 66     BRAZIL 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 67     BRAZIL 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 68     REST OF LATIN AMERICA 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 69     REST OF LATIN AMERICA 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 70     MIDDLE EAST AND OTHERS 3D CELL CULTURE MARKET REVENUE, BY TECHNOLOGY, BY END-USERS & BY PRODUCTS (2017 VS 2024) ($MN)
      • FIGURE 71     MIDDLE EAST AND OTHERS 3D CELL CULTURE MARKET REVENUE, BY APPLICATIONS (2017 VS 2024) ($MN)
      • FIGURE 72     KEY GROWTH STRATEGIES, (JAN 2016 – JAN 2018)
      • FIGURE 73     OVERVIEW: BECTON DICKINSON AND COMPANY
      • FIGURE 74     SWOT: BECTON DICKINSON AND COMPANY
      • FIGURE 75     OVERVIEW: CORNING INCORPORATED
      • FIGURE 76     SWOT: CORNING INCORPORATED
      • FIGURE 77     SWOT: INSPHERO AG
      • FIGURE 78     SWOT: ORGANOGENIX INC.
      • FIGURE 79     OVERVIEW: KURARAY CO. LTD
      • FIGURE 80     SWOT: KURARAY CO. LTD
      • FIGURE 81     OVERVIEW: LONZA GROUP
      • FIGURE 82     SWOT: LONZA GROUP
      • FIGURE 83     OVERVIEW: MERCK KGAA
      • FIGURE 84     SWOT: MERCK KGAA
      • FIGURE 85     SWOT: NANO 3D BIOSCIENCES
      • FIGURE 86     OVERVIEW: ORGANOVO HOLDINGS INC.
      • FIGURE 87     SWOT: ORGANOVO HOLDINGS INC
      • FIGURE 88     OVERVIEW: THERMO FISHER SCIENTIFIC INC
      • FIGURE 89     SWOT: THERMO FISHER SCIENTIFIC, INC

        LIST OF COMPANIES MENTIONED IN THE REPORT

        • 1     300 MICRONS GMBH
        • 2     3D BIOTEK, LLC
        • 3     3D MATRIX CO.
        • 4     3DTRO AB
        • 5     ADVANCED BIOMATRIX, INC.
        • 6     AIM BIOTECH PTE LTD.
        • 7     AKRON BIOTECHNOLOGY, LLC
        • 8     AMSBIO LLC
        • 9     ASCENDANCE
        • 10     ASPECT BIOSYSTEMS
        • 11     ASTERAND BIOSCIENCE
        • 12     AVANTICELL SCIENCE
        • 13     BASF
        • 14     BECTON, DICKINSON AND COMPANY
        • 15     BELLBROOKS LABS
        • 16     BELLCO GLASS, INC
        • 17     BIOCELLCHALLENGE
        • 18     BIOGELX LTD.
        • 19     BIOLAMINA AB
        • 20     BIOMERIX
        • 21     BIOVISION, INC.
        • 22     BIOZOL GMBH
        • 23     BISS TGT
        • 24     BRTI LIFE SCIENCES
        • 25     CELARTIA
        • 26     CELL APPLICATIONS, INC.
        • 27     CELL BIO LABS
        • 28     CELL SPRING
        • 29     CELLECBIOTEK AG
        • 30     CELLENDES GMBH
        • 31     CELLEVATE AB
        • 32     CELLINK
        • 33     CELLNTEC ADVANCED CELL SYSTEMS AG
        • 34     CELPROGEN
        • 35     CELVIVO IVS
        • 36     CHARLES RIVER LABORATORIES
        • 37     CNBIO INNOVATIONS LTD.
        • 38     CORNING INC.
        • 39     CTIBIOTECH
        • 40     CYFUSE BIOMEDICAL KK
        • 41     CYTOO
        • 42     DIA GENODE
        • 43     DWK LIFE SCIENCES
        • 44     EBERS MEDICAL TECHNOLOGY SL
        • 45     ECTICA TECHNOLOGIES AG
        • 46     ELECTROSPINNING COMPANY
        • 47     EMULATE, INC.
        • 48     ESI BIO
        • 49     FIBERCELL SYSTEMS INC.
        • 50     FLUIDINOVA SA
        • 51     FUJIFILM
        • 52     GENLANTIS (GENE THERAPY SYSTEMS, INC.)
        • 53     GLOBAL CELL SOLUTIONS, INC
        • 54     GRADIENTECH AB
        • 55     GREINER BIO-ONE GMBH
        • 56     GUANGZHOU JET BIO-FILTRATION CO., LTD.
        • 57     KERANETICS
        • 58     HOKKAIDO SODA
        • 59     HUREL CORP
        • 60     IBIDI GMBH
        • 61     INSPHERO
        • 62     INVIVO SCIENCES
        • 63     IRVINE SCIENTIFIC
        • 64     IV TECH SRL
        • 65     JAPAN VILENE COMPANY
        • 66     JSR CORPORATION (ORGANOGENIX INC.)
        • 67     KIRKSTALL LTD
        • 68     KOKEN CO. LTD.
        • 69     KOLLOIDIS BIOSCIENCES
        • 70     KURARAY CO., LTD.
        • 71     LENA BIOSCIENCES, INC.
        • 72     LIFECORE BIOMEDICAL,
        • 73     LOCATE THERAPEUTICS
        • 74     LONZA GROUP
        • 75     MATRICEL GMBH
        • 76     MATTEK CORPORATION
        • 77     MENICON LIFE SCIENCE
        • 78     MERCK KGAA
        • 79     MICROTISSUES, INC.
        • 80     MILTENYI BIOTEC GMBH
        • 81     MIMETAS B.V.
        • 82     MIRUS BIO
        • 83     NANO 3D BIOSCIENCES INC
        • 84     NANOFIBER SOLUTIONS
        • 85     NANOLIVE SA
        • 86     NANOPHARMA A.S.
        • 87     NEUROMICS INC
        • 88     ORGANOVO HOLDINGS, INC
        • 89     PEPGEL LLC
        • 90     PERKINELMER
        • 91     PISHON BIOMEDICAL
        • 92     PRODIZEN
        • 93     PROMEGA CORPORATION
        • 94     PROMOCELL GMBH
        • 95     PROTISTA INTERNATIONAL AB
        • 96     QGEL BIO
        • 97     QUORUS BIOTECH (PTY) LTD.
        • 98     REALBIO TECHNOLOGY INC.
        • 99     REGENOVO
        • 100     REPROCELL (REINNERVATE LTD. )
        • 101     SANGI CO., LTD.
        • 102     SARTORIUS STEDIM BIOTECH
        • 103     STEMCELL TECHNOLOGIES INC.
        • 104     STEMTEK
        • 105     SUMITOMO BAKELITE CO. LTD.
        • 106     SYNTHECON, INC
        • 107     SYNVIVO LLC
        • 108     TAKARA BIO INC (CLONTECH)
        • 109     TETEC AG (B BRAUN)
        • 110     THE WELL BIOSCIENCE INC.
        • 111     THERMO FISHER SCIENTIFIC
        • 112     TREVIGEN, INC.
        • 113     UPM
        • 114     VORNIA BIOMATERIALS LTD.
        • 115     XANOFI
        • 116     ZPREDICTA, INC.